[Therapeutic effects of small interfering RNA targeting MDM2 on human osteosarcoma cells]

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Osteosarcoma is a primary malignant bone tumor with limited treatment options.
• The mdm2 gene plays a crucial role in regulating cell growth and survival, and its overexpression is implicated in various cancers, including osteosarcoma.

Purpose of the Study:

• To evaluate the efficacy of small interfering RNA (siRNA) targeting the mdm2 gene in inhibiting osteosarcoma cell proliferation and inducing apoptosis.
• To assess the therapeutic potential of mdm2-targeting siRNA in a preclinical model of osteosarcoma.

Main Methods:

• Construction and transfection of PGCsilencerTM-mdm2 siRNA into U2OS osteosarcoma cells.
• Assessment of mdm2 gene and protein expression using RT-PCR and Western blot.
• Evaluation of cell proliferation and apoptosis via MTT assay and flow cytometry.
• In vivo efficacy study using a xenograft nude mouse model.

Main Results:

• Successful construction and transfection of mdm2-targeting siRNA.
• Significant inhibition of mdm2 gene and protein expression in U2OS cells.
• Reduced cell growth activity and increased apoptosis in treated cells.
• Inhibition of tumor growth and down-regulation of mdm2 expression in xenograft tumors.

Conclusions:

• siRNA targeting the mdm2 gene demonstrates potent inhibitory effects on osteosarcoma cell growth.
• MDM2 inhibition via siRNA represents a promising therapeutic strategy for osteosarcoma.